Drug-drug interaction study between AT2220 and ERT
AN OPEN-LABEL MULTI-CENTER, INTERNATIONAL STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT2220 AND ALGLUCOSIDASE ALFA IN PATIENTS WITH POMPE DISEASE AN OPEN-LABEL MULTI-CENTER, INTERNATIONAL STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT2220 ...
An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions Between AT2220 and Alglucosidase Alfa in Patients With Pompe Disease An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions Between AT222 ...
Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
An Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Three Dosing Regimens of Oral AT2220 in Patients With Pompe Disease An Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmac ...
Pompe Disease
Drug: Duvoglustat
Amicus Therapeutics
NULL
Terminated
18 Years
74 Years
All
3
Phase 2
United States;Australia;Canada;France;Germany;Netherlands;United Kingdom
A dose finding study with intravenous administration of duvoglustat hydrochloride (AT2220) and Myozyme in Pompe patients A dose finding study with intravenous administration of duvoglustathydrochloride (AT2220) and Myozym ...
AN OPEN-LABEL SAFETY AND DOSE-FINDING STUDY OF INTRAVENOUS DUVOGLUSTAT CO-ADMINISTERED WITH RECOMBINANT HUMAN ACID a-GLUCOSIDASE IN SUBJECTS WITH POMPE DISEASE AN OPEN-LABEL SAFETY AND DOSE-FINDING STUDY OF INTRAVENOUS DUVOGLUSTATCO-ADMINISTERED WITH RECOMBINA ...